Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC

SIMPLE SUMMARY: Despite initial tumor regression following androgen blockade treatment, relapse of castration-resistant prostate cancer (CRPC) eventually occurs in most patients. Immunotherapy aims to activate the host immune system to fight against cancer and has achieved significant therapeutic ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Lilv, Xu, Guiliang, Cao, Jingjing, Li, Min, Zhang, Huihui, Li, Fanlin, Qi, Xinyue, Zhang, Xiaoqing, Li, Zeyu, Han, Ping, Yang, Xuanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582786/
https://www.ncbi.nlm.nih.gov/pubmed/34771735
http://dx.doi.org/10.3390/cancers13215574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582786/
https://www.ncbi.nlm.nih.gov/pubmed/34771735
http://dx.doi.org/10.3390/cancers13215574

Ejemplares similares